Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.3%
    Check dated 2025-05-01T03:50:13.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.
    Difference
    1.0%
    Check dated 2025-04-16T14:30:08.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 20, 2025.
    Difference
    0.6%
    Check dated 2025-04-09T09:20:34.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The page has updated the reference to Seagen, clarifying its relationship as a subsidiary of Pfizer, and has changed a date from February 20, 2025, to March 20, 2025.
    Difference
    3%
    Check dated 2025-03-25T13:57:13.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The webpage has removed a notice regarding heavy traffic affecting certain services and products, as well as a specific date. Additionally, a new date has been added.
    Difference
    6%
    Check dated 2025-02-24T21:05:06.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The webpage now includes a notice about heavy traffic affecting NLM-NCBI services and products, along with a contact for assistance. Additionally, a date has been added, while a previous date has been removed.
    Difference
    7%
    Check dated 2025-02-10T09:58:30.000Z thumbnail image

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.